Date: 2015-10-19
Type of information: Nomination
Compound:
Company: BioTime (USA - CA)
Therapeutic area: Regenerative Medicine
Type agreement: nomination
Action mechanism:
Disease:
Details: * On October 19, 2015, BioTime, a clinical-stage regenerative medicine company with a focus on pluripotent stem cell technology, reported that its Board of Directors has appointed Adi Mohanty to serve with Michael D. West , PhD, as co-Chief Executive Officer. Mr. Mohanty has served as BioTime\'s Chief Operating Officer since December 2014 . Dr. West will lead BioTime\'s science, technology development, and intellectual property activities with a particular focus on growing the company\'s discovery and pre-clinical product development programs. Mr. Mohanty will lead the company\'s advanced clinical development programs and commercialization strategies, as well as assume leadership of its corporate and administrative activities. The two executives will continue to collaborate closely on major corporate decisions, and both will report to the Board of Directors.
Prior to joining BioTime and particularly during his 11 years at Shire plc , Mr. Mohanty served in various leadership positions of increasing responsibility. At Shire, he most recently served as President, Head of the Regenerative Medicine Business, where he oversaw all aspects of that concern, including sales and marketing, research and development, and manufacturing. Mr. Mohanty led a successful turnaround and divestiture of that division. Prior to that achievement, Mr. Mohanty served as the head of Shire\'s global franchise portfolio of biologic products for rare diseases, with sales and operations in over 50 countries. Previously, Mr. Mohanty served in management positions at Transkaryotic Therapies, Inc. , a development-stage biotherapeutics enterprise that grew to a successful commercial company eventually acquired by Shire. Before joining Transkaryotic Therapies, Mr. Mohanty worked at Baxter Bioscience (now Baxalta ), where he held a variety of engineering, manufacturing, and general management positions. He has been involved in the development of several successful products through clinical trials and launch, and in later-stage, life-cycle management of products addressing patient needs in the context of several rare diseases and wound care. Mr. Mohanty holds BS and MS degrees in Chemical Engineering as well as an MBA.
Financial terms:
Latest news:
